Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Amicus
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: FOLD
Last verified 14 days agoamicusrx.com
Amicus, officially known as Amicus Therapeutics, Inc., is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in the United States. Founded in 2002, the company has made significant strides in developing innovative therapies for rare and orphan diseases, particularly in the field of enzyme replacement therapies.
With a strong operational presence across North America and Europe, Amicus is renowned for its unique approach to drug development, focusing on precision medicine and patient-centric solutions. Their flagship products, including Galafold, exemplify their commitment to addressing unmet medical needs with cutting-edge technology.
Recognised for its robust pipeline and strategic partnerships, Amicus has established itself as a leader in the biopharmaceutical sector, continually striving to improve the lives of patients worldwide.
26
DitchCarbon score
-16 vs industry average
Amicus’s score of 26 is lower than 38% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Amicus?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2020
2020
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Amicus's reported carbon emissions
Amicus, a US-based pharmaceutical preparation manufacturing company, reported approximately 302,400 kg CO2e in total emissions for 2020. This data, disclosed in their 2022 ESG Report, does not specify breakdowns for Scope 1, Scope 2, or Scope 3 emissions, and indicates missing data points for Scope 1, Scope 2, and Scope 3 purchased goods and services. Amicus has not publicly committed to any specific emissions reduction targets, such as those validated by the Science Based Targets initiative (SBTi).
Assessing Amicus as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Amicus and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Amicus’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Amicus yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Amicus14 days ago
26
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more